ANORO ELLIPTA Drug Patent Profile

When do Anoro Ellipta patents expire, and what generic alternatives are available?

Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are five patents protecting this drug.

This drug has two hundred and one patent family members in forty-nine countries.

The generic ingredient in ANORO ELLIPTA is umeclidinium bromide; vilanterol trifenatate. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the umeclidinium bromide; vilanterol trifenatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Anoro Ellipta

Anoro Ellipta was eligible for patent challenges on May 10, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 29, 2030. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ANORO ELLIPTA

International Patents:	201
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	50
Patent Applications:	516
Drug Prices:	Drug price information for ANORO ELLIPTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ANORO ELLIPTA
What excipients (inactive ingredients) are in ANORO ELLIPTA?	ANORO ELLIPTA excipients list
DailyMed Link:	ANORO ELLIPTA at DailyMed

See drug prices for ANORO ELLIPTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ANORO ELLIPTA

Constraining patent/regulatory exclusivity:

9,750,726

NDA:

203975

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ANORO ELLIPTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Alabama at Birmingham	PHASE2
GlaxoSmithKline	PHASE4
University of Tennessee Graduate School of Medicine	PHASE4

See all ANORO ELLIPTA clinical trials

Pharmacology for ANORO ELLIPTA

Drug Class	Anticholinergic beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists

US Patents and Regulatory Information for ANORO ELLIPTA

ANORO ELLIPTA is protected by five US patents.

This potential generic entry date is based on patent 9,750,726.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes	11,090,294
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes	12,396,986		Y
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes	9,750,726		Y
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes	7,488,827		Y	Y

Expired US Patents for ANORO ELLIPTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013	5,873,360
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013	8,309,572
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013	7,361,787
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013	8,183,257

International Patents for ANORO ELLIPTA

When does loss-of-exclusivity occur for ANORO ELLIPTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Norway

Peru

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Turkey

Ukraine

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ANORO ELLIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	0317374
Japan	2005527260
China	1585633
Costa Rica	20120265	COMBINACIONES DE UN ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y UN AGONISTA DEL ADRENO-RECEPTOR BETA-2

Supplementary Protection Certificates for ANORO ELLIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1740177	C 2014 041	Romania		PRODUCT NAME: BROMURADE UMECLIDINIUM4-[HIDROXI(DIFENIL)METIL]-1-{2-[(FENILMETIL)OXI]ETIL}-1-AZONIABI DATE OF NATIONAL AUTHORISATION: 20140428; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (CICLO[2.2.2]OCTAN; NATIONAL AUTHORISATION NUMBER: EU/1/14/922/001, EU/1/14/922/002, EU/1/14/922/003;EEA): EU/1/14/922/001, EU/1/14/922/002, EU/1/14/922/003; DATE OF FIRST AUTHORISATION IN EEA: 20140428
1740177	C01740177/02	Switzerland		PRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
1425001	174 50004-2014	Slovakia		PRODUCT NAME: VILANTEROLTRIFENATAT; REGISTRATION NO/DATE: EU/1/13/886/001 - EU/1/13/886/006 20131113

Market Dynamics and Financial Trajectory for ANORO ELLIPTA

Last updated: January 5, 2026

---

Summary

ANORO ELLIPTA (umeclidinium and vilanterol) is a combination inhaler approved for chronic obstructive pulmonary disease (COPD) treatment. Since its FDA approval in 2016, it has become a key agent in COPD management, influenced by evolving market dynamics, regulatory policies, competitive landscape, and clinical data. This analysis examines its current market position, trajectory, and underlying drivers shaping its financial prospects over the coming years.

---

Introduction to ANORO ELLIPTA

• Drug Composition: Umeclidinium (LAMAb) + Vilanterol (LABA)
• Indication: COPD (including chronic bronchitis and emphysema)
• Approval Date: July 2016 (FDA)
• Manufacturers: AstraZeneca (primary), with licensing agreements involving GlaxoSmithKline (GSK) for distribution in some regions

Market Overview

Key Parameters	Data/Details
Global COPD Market Size (2022)	~$9.2 billion (MarketsandMarkets)
ANORO ELLIPTA Sales (2022)	~$2 billion (IQVIA)
Market Penetration (U.S.)	Estimated at 20-25% of COPD inhaler market
Key Competitors	Spiriva (GSK), Advair (GSK), Breo Ellipta (GSK), Trelegy (GSK)

Market Dynamics Influencing ANORO ELLIPTA

Regulatory Environment

• FDA Approvals & Label Updates: Expanded indications for COPD severity stages.
• Pricing & Reimbursement: Influenced by healthcare policies; U.S. Medicare discount programs favor inhalers with proven adherence benefits.
• Biosimilar & Generic Threats: Limited due to complex inhaler device patents; major patents expire from 2025 onward.

Market Penetration & Adoption Drivers

Drivers	Impact
Clinical Efficacy	Proven to improve lung function and reduce exacerbations
Device Design & Adherence	Dry powder inhaler (DPI) facilitates ease of use, enhancing adherence
Physician Preference	Favoring LAMA/LABA combinational therapies as initial COPD management
Patient Demographics	Aging populations increase COPD prevalence, expanding market size

Competitive Landscape

Product	Manufacturer	Formulation	Market Share (2022)	Key Advantages	Limitations
ANORO ELLIPTA	AstraZeneca	LAMA/LABA	~22%	Once-daily dosing, ease of use	Competition from Trelegy (triple therapy)
Spiriva	GSK	LAMA	~25%	Long-standing market presence	Does not combine LABA
Breo Ellipta	GSK	ICS/LABA	~19%	Broad COPD and asthma coverage	Higher corticosteroid exposure

Technological & Innovation Trends

• Device Innovation: Developments like smart inhalers to track adherence.
• Combination Therapies: Rising preference for triple therapy (ICS + LABA + LAMA) impacting inhaler sales.

Financial Trajectory Analysis

Revenue Growth Forecast

Year	Estimated Revenue (USD)	Growth Rate	Assumptions
2023	~$2.2 billion	+10%	Continued market penetration, new regional approvals
2024	~$2.4 billion	+9%	Expansion into emerging markets
2025	~$2.6 billion	+8%	Patent protections, moderate competition impact
2026-2030	Stabilizing or modest growth (~5%)	Market saturation, biosimilar entry in late 2020s

Market Share Evolution

• Drivers: Increasing COPD prevalence (WHO estimates 200 million globally), rising adoption of inhaled therapies, expanding indications.
• Challenges: Patent expiry risks, competitive innovation, shift towards triple therapies, biosimilars.

Pricing & Reimbursement Dynamics

• Pricing Strategies: Premium positioning based on device ease, adherence benefits.
• Reimbursement Trends: Favoring cost-effective therapies, incentivizing adherence improvements.

Global Market Considerations

Region	Market Size (2022 USD)	Expected CAGR (2023-2028)	Key Factors
North America	~$4 billion	6-8%	High COPD prevalence, strong healthcare infrastructure
Europe	~$2.5 billion	4-6%	Regulatory diversity, reimbursement variability
Asia-Pacific	~$1.2 billion	10-12%	Growing COPD awareness, rising smoking rates
Rest of World	~$0.5 billion	8-10%	Emerging economies, increasing healthcare access

PESTEL Analysis of ANORO ELLIPTA Market

Factor	Impact
Political	Favorable policies for respiratory disease management
Economic	Growing healthcare expenditure in emerging markets
Social	Aging populations increasing COPD cases
Technological	Innovation in inhaler device technology
Environmental	Sustainable device manufacturing practices
Legal	Patent protections, regulatory compliance

---

Comparison with Key Competitors

Aspect	ANORO ELLIPTA	Trelegy (GSK)	Spiriva (GSK)	Advair (GSK)
Formulation	LAMA/LABA	Triple therapy (LAMA/LABA/ICS)	LAMA	ICS/LABA
Dosing	Once daily	Once daily	Once daily	Twice daily
Market Share (2022)	~22%	~18%	~25%	~12%
Advantages	Ease of use, adherence	Broad spectrum, triple therapy	Long shelf life	Well-established brand
Limitations	Limited to COPD	Higher cost	No LABA component	Steroid-related side effects

---

Regulatory & Policy Impact

• Upcoming Patent Expiry: Significant patents for umeclidinium and vilanterol set to expire by 2025-2026, enabling generics/Biosimilars entry.
• Inhaler Device Guidelines: Regulatory agencies emphasizing device efficacy and safety, favoring innovation.
• Reimbursement Policies: Shift towards value-based care influencing formulary placements.

Forecasting Key Financial Metrics

Metric	2022	2023	2025	2030	Notes
Revenue (USD Billion)	2.0	2.2	2.6	3.2	Driven by market growth, patent protections
Market Share	22%	23%	25%	22%	Competitive pressures, biosiolars
R&D Investment (USD Million)	150	150	150	150+	Focus on inhaler technology, formulations

---

Key Factors Shaping Financial Trajectory

Factor	Influence	Strategic Implications
Patent Lifespan	Extends revenue window until 2025-2026	Need for lifecycle management strategies
Competition	Growing presence of triple therapy inhalers	Diversification into related formulations necessary
Regional Expansion	Emerging markets show high growth potential	Focused marketing and regulatory approval strategies
Innovation	Device and formulation improvements	Maintain competitive edge with smart inhalers, fixed-dose combinations

---

Conclusion

ANORO ELLIPTA sustains a solid market position primarily through its efficacy, user-friendly device, and strategic focus on COPD management. Its financial trajectory is expected to progress consistently through 2025, characterized by a compound annual growth rate (CAGR) of approximately 8-10%, driven by expanding global COPD prevalence and regional market penetration. However, patent expiry and intensifying competition, especially from triple therapy combinations and biosimilars, warrant proactive lifecycle management strategies and innovation investments.

---

Key Takeaways

• Market Position: ANORO ELLIPTA commands a significant segment of the COPD inhaler market, with stable growth prospects up to 2025.
• Growth Drivers: Increasing COPD prevalence, technological innovation, and expanding regional markets underpin growth.
• Challenges: Patent expiries, competition from triple therapy inhalers, and regulatory shifts impose downward pressure on revenue.
• Strategic Recommendations: Focus on lifecycle extension through formulation improvements, expand into emerging markets, and invest in digital and smart inhaler technology.
• Long-term Outlook: Revenue stabilization expected post-2025, with gradual market share adjustments due to biosimilar entry and evolving treatment paradigms.

---

FAQs about ANORO ELLIPTA

Q1: What are the main factors contributing to ANORO ELLIPTA’s market growth?
A: Factors include its clinical efficacy, ease of use via a dry powder inhaler, increasing COPD prevalence, and expanding global markets, especially in Asia-Pacific regions.

Q2: How will patent expiries affect ANORO ELLIPTA’s revenue?
A: Patent expiries around 2025-2026 could lead to biosimilar and generic competition, likely reducing prices and market share, necessitating lifecycle management.

Q3: How does ANORO ELLIPTA compare with triple therapy inhalers?
A: While ANORO is a dual therapy (LAMA/LABA), triple therapy inhalers (e.g., Trelegy) combine ICS, LABA, LAMA for more severe COPD cases. The latter may gain preference for advanced disease but face patent and reimbursement challenges.

Q4: What role do regional markets play in the financial outlook?
A: Emerging markets like Asia-Pacific exhibit high CAGR (~10-12%) and offer growth opportunities, especially where COPD prevalence is rising, and healthcare access is expanding.

Q5: What strategic moves can AstraZeneca consider to sustain competitiveness?
A: Innovating inhaler device technology, exploring fixed-dose combinations, expanding indications, and tailoring regional strategies will be vital for maintaining growth momentum.

---

References

1. MarketsandMarkets. COPD therapeutics market size and forecast (2022).
2. IQVIA. Global sales data for COPD inhalers (2022).
3. WHO. COPD prevalence and statistics (2022).
4. FDA. ANORO ELLIPTA approval and labeling updates (2016).
5. AstraZeneca Annual Reports (2022, 2023).